JENNA VEGA: Open Payments
NPI 1609418375 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,244 in 43 payments from 7 companies in 2025. Trend: 2023 $1,452 · 2024 $645 · 2025 $1,244
Food & beverage: $1,244
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $342 |
| E.R. Squibb & Sons, L.L.C. | 17 | $282 |
| Teva Pharmaceuticals USA, Inc. | 5 | $216 |
| Alkermes, Inc. | 5 | $203 |
| Otsuka America Pharmaceutical, Inc. | 3 | $145 |
| Lundbeck LLC | 2 | $40 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
Products named: INGREZZA, COBENFY, UZEDY, LYBALVI, ABILIFY MAINTENA, ARISTADA, ABILIFY ASIMTUFII, ERZOFRI EXTENDED-RELEASE.
Industry payments across LA — which companies pay providers there.
